- Home
- ADV vs CDNA Comparison
ADV vs CDNA Comparison
Compare ADV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | CDNA |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | 69000 | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.6M | 1.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ADV | CDNA |
|---|---|---|
| Price | $0.78 | $17.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $1.83 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 796.8K | 543.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $15.37 |
| Revenue Next Year | $1.22 | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $0.49 | $10.96 |
| 52 Week High | $2.11 | $21.49 |
Technical Indicators
Market Signals| Indicator | ADV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 40.44 |
| Support Level | $0.51 | $16.74 |
| Resistance Level | $0.97 | $20.94 |
| Average True Range (ATR) | 0.08 | 0.80 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 81.83 | 34.48 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.